Table 1.
Clinical characteristics of 16 patients with ovarian cancer
| Patient | Age at cancer | PNS | Histology | FIGO | Testing of patients sera | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| IB | IF | RIA | RIA | WB | WB | |||||
| CDR2 | CDR2/2L | CDR2 | CDR2L | CDR2 | CDR2L | |||||
| Yo1 | 60 | PCD | HGSC | 3A | + | + | + | + | + | + |
| Yo2 | 78 | None | HGSC | 3B | + | + | + | + | − | − |
| Yo3 | 58 | None | HGSC | 4 | + | + | + | + | + | + |
| Yo4 | 76 | PCD | HGSC | 3C | + | + | + | + | + | + |
| Yo5 | 78 | PCD | HGSC | 3C | + | + | ND | ND | + | + |
| Yo6 | 65 | PCD | HGSC | 3C | + | + | ND | ND | + | + |
| CDR2L1 | 74 | None | Carcinosarcoma | 3C | − | − | − | + | − | − |
| CDR2L2 | 72 | None | HGSC | 3C | − | − | − | + | − | − |
| CDR2L3 | 57 | None | HGSC | 4 | −a | − | − | + | − | − |
| CDR2L4 | 54 | None | Clear cell-carcinoma | 1A | − | − | − | + | − | − |
| CDR2L5 | 69 | None | HGSC | 3C | − | − | − | + | − | − |
| Control1 | 56 | None | HGSC | 3C | − | − | − | − | − | − |
| Control2 | 78 | None | HGSC | 4 | − | − | − | − | − | − |
| Control3 | 69 | None | HGSC | 1A | − | − | − | − | − | − |
| Control4 | 64 | None | HGSC | 3C | − | − | − | − | − | − |
| Control5 | 57 | None | HGSC | 3C | − | − | − | − | − | − |
IB immunoblot, IF immunofluorescence, ND no data, WB western blot
Ovarian cancer characteristics, including CDR2 expression, have been published earlier for patients Yo1-3, CDR2L4-5, Control1-2 and Control4-5, and data on CDR2L antibodies detected with different techniques have been published earlier for patient CDR2L1-5 [10, 13, 14]
a Zic4 antibody